Current challenges in pediatric pulmonary hypertension

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 5, 2013, Pages 627-644

  Takatsuki, Shinichi ^a,b   Ivy, Daviddunbar ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

children; congenital heart disease; pediatric pulmonary vascular disease; pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SILDENAFIL; THROMBOXANE A2; TREPROSTINIL;

ARTICLE; CATHETER INFECTION; CHILDHOOD DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; EUROPE; EXERCISE TOLERANCE; FUNCTIONAL STATUS; HEART CATHETERIZATION; HEART INDEX; HEART LUNG TRANSPLANTATION; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; IDIOPATHIC DISEASE; IMMUNOCOMPETENT CELL; LUNG ARTERY PRESSURE; LUNG DYSPLASIA; LUNG EDEMA; LUNG HEMODYNAMICS; MULTICENTER STUDY (TOPIC); NETHERLANDS; OXYGEN CONSUMPTION; PERSISTENT PULMONARY HYPERTENSION; PORTOPULMONARY HYPERTENSION; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDERED BREATHING; SUPPRESSOR CELL; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE; THROMBOEMBOLISM; TREATMENT RESPONSE; UNITED STATES; WORLD HEALTH ORGANIZATION;

CHILD; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; PHOSPHODIESTERASE 5 INHIBITORS; PROGNOSIS; PROSTAGLANDINS I; RECEPTORS, ENDOTHELIN; VASODILATOR AGENTS;

EID: 84884228624     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1356461     Document Type: Article

References (146)

1. Barst R. J., McGoon M. D., Elliott C. G., Foreman A. J., Miller D. P., Ivy D. D. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation: 2012; 125 1 113 122
2. Berger R. M., Beghetti M., Humpl T., et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet: 2012; 379 9815 537 546
3. Haworth S. G., Hislop A. A. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart: 2009; 95 4 312 317
4. Fraisse A., Jais X., Schleich J. M., et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis: 2010; 103 2 66 74
5. D'Alonzo G. E., Barst R. J., Ayres S. M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med: 1991; 115 5 343 349
6. Simonneau G., Robbins I. M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol: 2009; 54 (1, Suppl): S43 S54
7. McLaughlin V. V., Archer S. L., Badesch D. B., et al. American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol: 2009; 53 17 1573 1619
8. Cerro M. J., Abman S., Diaz G., et al. A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ: 2011; 1 2 286 298
9. van Albada M. E., Berger R. M. Pulmonary arterial hypertension in congenital cardiac disease-the need for refinement of the Evian-Venice classification. Cardiol Young: 2008; 18 1 10 17
10. Schulze-Neick I., Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart-cleaning up a dog's dinner. Cardiol Young: 2008; 18 1 22 25
11. Badesch D. B., Champion H. C., Sanchez M. A., et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol: 2009; 54 (1, Suppl): S55 S66
12. Beghetti M., Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol: 2009; 53 9 733 740
13. Hassoun P. M., Mouthon L., Barberà J. A., et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol: 2009; 54 (1, Suppl): S10 S19
14. Humbert M., Morrell N. W., Archer S. L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol: 2004; 43 (12, Suppl S): 13S 24S
15. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol: 2007; 2 369 399
16. Diller G. P., Thum T., Wilkins M. R., Wharton J. Endothelial progenitor cells in pulmonary arterial hypertension. Trends Cardiovasc Med: 2010; 20 1 22 29
17. Diller G. P., van Eijl S., Okonko D. O., et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation: 2008; 117 23 3020 3030
18. Lavoie J. R., Stewart D. J. Genetically modified endothelial progenitor cells in the therapy of cardiovascular disease and pulmonary hypertension. Curr Vasc Pharmacol: 2012; 10 3 289 299
19. Smadja D. M., Mauge L., Gaussem P., et al. Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis: 2011; 14 1 17 27
20. Stewart D. J., Zhao Y. D., Courtman D. W. Cell therapy for pulmonary hypertension: what is the true potential of endothelial progenitor cells? Circulation: 2004; 109 172 173
21. Zhu J. H., Wang X. X., Zhang F. R., et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant: 2008; 12 6 650 655
22. Lama V. N., Phan S. H. The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc: 2006; 3 4 373 376
23. Moeller A., Gilpin S. E., Ask K., et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med: 2009; 179 7 588 594
24. Yeager M. E., Nguyen C. M., Belchenko D. D., et al. Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest: 2012; 141 4 944 952
25. Yeager M. E., Nguyen C. M., Belchenko D. D., et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J: 2012; 39 1 104 111
26. van Loon R. L., Roofthooft M. T., Hillege H. L., et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation: 2011; 124 16 1755 1764
27. Moledina S., Hislop A. A., Foster H., Schulze-Neick I., Haworth S. G. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart: 2010; 96 17 1401 1406
28. Sandoval J., Bauerle O., Gomez A., Palomar A., Martínez Guerra M. L., Furuya M. E. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol: 1995; 25 2 466 474
29. Lammers A. E., Adatia I., Cerro M. J., et al. Functional classification of pulmonary hypertension in children: Report from the PVRI pediatric taskforce, Panama 2011. Pulm Circ: 2011; 1 2 280 285
30. van Loon R. L., Roofthooft M. T., Delhaas T., et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol: 2010; 106 1 117 124
31. Bernus A., Wagner B. D., Accurso F., Doran A., Kaess H., Ivy D. D. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest: 2009; 135 3 745 751
32. Lammers A. E., Hislop A. A., Haworth S. G. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol: 2009; 135 1 21 26
33. Takatsuki S., Wagner B. D., Ivy D. D. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis: 2012; 7 3 259 267
34. Van Albada M. E., Loot F. G., Fokkema R., Roofthooft M. T., Berger R. M. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res: 2008; 63 3 321 327
35. Takatsuki S., Ivy D. D., Nuss R. Correlation of N-terminal fragment of B-type natriuretic peptide levels with clinical, laboratory, and echocardiographic abnormalities in children with sickle cell disease. J Pediatr: 2012; 160 3 428 433, e1
36. Yeager M. E., Colvin K. L., Everett A. D., Stenmark K. R., Ivy D. D. Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics Clin Appl: 2012; 6 5-6 257 267
37. Forfia P. R., Fisher M. R., Mathai S. C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med: 2006; 174 9 1034 1041
38. Dyer K. L., Pauliks L. B., Das B., et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. J Am Soc Echocardiogr: 2006; 19 1 21 27
39. Lammers A. E., Haworth S. G., Riley G., Maslin K., Diller G. P., Marek J. Value of tissue Doppler echocardiography in children with pulmonary hypertension. J Am Soc Echocardiogr: 2012; 25 5 504 510
40. Sachdev V., Machado R. F., Shizukuda Y., et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol: 2007; 49 4 472 479
41. Takatsuki S., Nakayama T., Jone P. N., et al. Tissue Doppler imaging predicts adverse outcome in children with idiopathic pulmonary arterial hypertension. J Pediatr: 2012; 161 6 1126 1131
42. Alkon J., Humpl T., Manlhiot C., McCrindle B. W., Reyes J. T., Friedberg M. K. Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension. Am J Cardiol: 2010; 106 3 430 436
43. Douwes J. M., van Loon R. L., Hoendermis E. S., et al. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria. Eur Heart J: 2011; 32 24 3137 3146
44. Dyer K., Lanning C., Das B., et al. Noninvasive Doppler tissue measurement of pulmonary artery compliance in children with pulmonary hypertension. J Am Soc Echocardiogr: 2006; 19 4 403 412
45. Gan C. T., Lankhaar J. W., Westerhof N., et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest: 2007; 132 6 1906 1912
46. Lankhaar J. W., Westerhof N., Faes T. J., et al. Pulmonary vascular resistance and compliance stay inversely related during treatment of pulmonary hypertension. Eur Heart J: 2008; 29 13 1688 1695
47. Lankhaar J. W., Westerhof N., Faes T. J., et al. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol: 2006; 291 4 H1731 H1737
48. Weinberg C. E., Hertzberg J. R., Ivy D. D., et al. Extraction of pulmonary vascular compliance, pulmonary vascular resistance, and right ventricular work from single-pressure and Doppler flow measurements in children with pulmonary hypertension: a new method for evaluating reactivity: in vitro and clinical studies. Circulation: 2004; 110 17 2609 2617
49. Mahapatra S., Nishimura R. A., Oh J. K., McGoon M. D. The prognostic value of pulmonary vascular capacitance determined by Doppler echocardiography in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr: 2006; 19 8 1045 1050
50. Mahapatra S., Nishimura R. A., Sorajja P., Cha S., McGoon M. D. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol: 2006; 47 4 799 803
51. Sajan I., Manlhiot C., Reyes J., McCrindle B. W., Humpl T., Friedberg M. K. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. Am Heart J: 2011; 162 3 562 568
52. Friedberg M. K., Feinstein J. A., Rosenthal D. N. Noninvasive assessment of pulmonary arterial capacitance by echocardiography. J Am Soc Echocardiogr: 2007; 20 2 186 190
53. Hunter K. S., Lee P. F., Lanning C. J., et al. Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. Am Heart J: 2008; 155 1 166 174
54. Rosenzweig E. B., Feinstein J. A., Humpl T., Ivy D. D. Pulmonary arterial hypertension in children: Diagnostic work-up and challenges. Prog Pediatr Cardiol: 2009; 27 1 4 11
55. Das B. B., Wolfe R. R., Chan K. C., Larsen G. L., Reeves J. T., Ivy D. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med: 2004; 158 12 1170 1176
56. Condino A. A., Ivy D. D., O'Connor J. A., et al. Portopulmonary hypertension in pediatric patients. J Pediatr: 2005; 147 1 20 26
57. Whitworth J. R., Ivy D. D., Gralla J., Narkewicz M. R., Sokol R. J. Pulmonary vascular complications in asymptomatic children with portal hypertension. J Pediatr Gastroenterol Nutr: 2009; 49 5 607 612
58. Tissot C., Ivy D. D., Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. J Pediatr: 2010; 157 4 528 532
59. Barst R. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? Int J Clin Pract Suppl: 2010; 64 168 23 32
60. Barst R. J., Maislin G., Fishman A. P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation: 1999; 99 9 1197 1208
61. Barst R. J., Rubin L. J., Long W. A., et al. Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med: 1996; 334 5 296 301
62. Barst R. J., Rubin L. J., McGoon M. D., Caldwell E. J., Long W. A., Levy P. S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med: 1994; 121 6 409 415
63. Ivy D. D., Claussen L., Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol: 2007; 99 5 696 698
64. Ivy D. D., Doran A., Claussen L., Bingaman D., Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol: 2004; 93 7 943 946
65. Lammers A. E., Hislop A. A., Flynn Y., Haworth S. G. Epoprostenol treatment in children with severe pulmonary hypertension. Heart: 2007; 93 6 739 743
66. Rosenzweig E. B., Kerstein D., Barst R. J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation: 1999; 99 14 1858 1865
67. Yung D., Widlitz A. C., Rosenzweig E. B., Kerstein D., Maislin G., Barst R. J. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation: 2004; 110 6 660 665
68. Ivy D. D. Prostacyclin in the intensive care setting. Pediatr Crit Care Med: 2010; 11 (2, Suppl): S41 S45
69. Barst R. J., Galie N., Naeije R., et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J: 2006; 28 6 1195 1203
70. Ivy D. D., Rosenzweig E. B., Lemarié J. C., Brand M., Rosenberg D., Barst R. J. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol: 2010; 106 9 1332 1338
71. Centers for Disease Control and Prevention (CDC) Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep: 2007; 56 8 170 172
72. Doran A. K., Ivy D. D., Barst R. J., Hill N., Murali S., Benza R. L.; Scientific Leadership Council of the Pulmonary Hypertension Association. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl: 2008; 160 5 9
73. Ivy D. D., Calderbank M., Wagner B. D., et al. Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension. Infect Control Hosp Epidemiol: 2009; 30 9 823 829
74. Rich J. D., Glassner C., Wade M., et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest: 2012; 141 1 36 42
75. Levy M., Celermajer D. S., Bourges-Petit E., Del Cerro M. J., Bajolle F., Bonnet D. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr: 2011; 158 4 584 588
76. Channick R. N., Olschewski H., Seeger W., Staub T., Voswinckel R., Rubin L. J. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol: 2006; 48 7 1433 1437
77. McLaughlin V. V., Benza R. L., Rubin L. J., et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol: 2010; 55 18 1915 1922
78. Krishnan U., Takatsuki S., Ivy D. D., et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol: 2012; 110 11 1704 1709
79. Beghetti M., Berner M., Rimensberger P. C. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. Heart: 2001; 86 3 E10
80. Hoeper M. M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med: 2000; 342 25 1866 1870
81. Ivy D. D., Doran A. K., Smith K. J., et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol: 2008; 51 2 161 169
82. Limsuwan A., Khosithseth A., Wanichkul S., Khowsathit P. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv: 2009; 73 1 98 104
83. Limsuwan A., Wanitkul S., Khosithset A., Attanavanich S., Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol: 2008; 129 3 333 338
84. Tissot C., Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag: 2009; 5 1 325 331
85. Rimensberger P. C., Spahr-Schopfer I., Berner M., et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation: 2001; 103 4 544 548
86. Archer S. L., Michelakis E. D. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med: 2009; 361 19 1864 1871
87. Michelakis E., Tymchak W., Archer S. Sildenafil: from the bench to the bedside. CMAJ: 2000; 163 9 1171 1175
88. Galiè N., Brundage B. H., Ghofrani H. A., et al. Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation: 2009; 119 22 2894 2903
89. Galiè N., Ghofrani H. A., Torbicki A., et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med: 2005; 353 20 2148 2157
90. Ivy D. D., Kinsella J. P., Ziegler J. W., Abman S. H. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg: 1998; 115 4 875 882
91. Atz A. M., Wessel D. L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology: 1999; 91 1 307 310
92. Namachivayam P., Theilen U., Butt W. W., Cooper S. M., Penny D. J., Shekerdemian L. S. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med: 2006; 174 9 1042 1047
93. Atz A. M., Lefler A. K., Fairbrother D. L., Uber W. E., Bradley S. M. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg: 2002; 124 3 628 629
94. Ghofrani H. A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet: 2002; 360 9337 895 900
95. Ciliberti P., Giardini A. Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. Future Cardiol: 2011; 7 5 609 612
96. Ciliberti P., Schulze-Neick I., Giardini A. Modulation of pulmonary vascular resistance as a target for therapeutic interventions in Fontan patients: focus on phosphodiesterase inhibitors. Future Cardiol: 2012; 8 2 271 284
97. Do P., Randhawa I., Chin T., Parsapour K., Nussbaum E. Successful management of plastic bronchitis in a child post Fontan: case report and literature review. Lung: 2012; 190 4 463 468
98. Giardini A., Balducci A., Specchia S., Gargiulo G., Bonvicini M., Picchio F. M. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J: 2008; 29 13 1681 1687
99. Goldberg D. J., French B., Szwast A. L., et al. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol: 2012; 33 5 689 696
100. Hager A., Fratz S., Hess J. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J: 2009; 30 4 507 508, author reply 508
101. Haseyama K., Satomi G., Yasukochi S., Matsui H., Harada Y., Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg: 2006; 132 5 1232 1233
102. Llamas J. P., Szkutnik M., Fiszer R., Białkowski J. Treatment of elevated pulmonary artery pressure in a child after Glenn procedure: transcatheter closure of pulmonary artery banding with subsequent sildenafil therapy. Kardiol Pol: 2012; 70 2 201 203
103. Morchi G. S., Ivy D. D., Duster M. C., Claussen L., Chan K. C., Kay J. Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology. Congenit Heart Dis: 2009; 4 2 107 111
104. Reinhardt Z., Uzun O., Bhole V., et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young: 2010; 20 5 522 525
105. Shabanian R., Shahbaznejad L., Razaghian A., et al. Sildenafil and Ventriculo-Arterial Coupling in Fontan-Palliated Patients: A Noninvasive Echocardiographic Assessment. Pediatr Cardiol: 2013; 34 1 129 134
106. Uzun O., Wong J. K., Bhole V., Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg: 2006; 82 6 e39 e40
107. Goldberg D. J., French B., McBride M. G., et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation: 2011; 123 11 1185 1193
108. Humpl T., Reyes J. T., Holtby H., Stephens D., Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation: 2005; 111 24 3274 3280
109. Karatza A. A., Bush A., Magee A. G. Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int J Cardiol: 2005; 100 2 267 273
110. Mourani P. M., Sontag M. K., Ivy D. D., Abman S. H. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr: 2009; 154 3 379 384, e1-e2
111. Satoh T., Saji T., Watanabe H., et al. A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. Circ J: 2011; 75 3 677 682
112. Barst R. J., Ivy D. D., Gaitan G., et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation: 2012; 125 2 324 334
113. Barst R., Layton G., Konourina I., Richardson H., Beghetti M., Ivy D. STARTS-2: Long-Term Survival With Oral Sildenafil Monotherapy in Treatment-Naive Patients With Pediatric Pulmonary Arterial Hypertension. Eur Heart J: 2012; 33 979
114. Steinhorn R. H., Kinsella J. P., Pierce C., et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr: 2009; 155 6 841 847, e1
115. Fraisse A., Butrous G., Taylor M. B., Oakes M., Dilleen M., Wessel D. L. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med: 2011; 37 3 502 509
116. Takatsuki S., Calderbank M., Ivy D. D. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol: 2012; 33 5 683 688
117. Pettit R. S., Johnson C. E., Caruthers R. L. Stability of an extemporaneously prepared tadalafil suspension. Am J Health Syst Pharm: 2012; 69 7 592 594
118. Channick R. N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet: 2001; 358 9288 1119 1123
119. Apostolopoulou S. C., Papagiannis J., Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant: 2005; 24 8 1174 1176
120. Barst R. J., Ivy D., Dingemanse J., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther: 2003; 73 4 372 382
121. Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol: 2009; 7 2 225 233
122. Beghetti M., Hoeper M. M., Kiely D. G., et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res: 2008; 64 2 200 204
123. D'Alto M., Romeo E., Argiento P., et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. Int J Cardiol: 2013; 164 3 323 326
124. Duffels M. G., Vis J. C., van Loon R. L., et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol: 2009; 134 3 378 383
125. Hislop A. A., Moledina S., Foster H., Schulze-Neick I., Haworth S. G. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J: 2011; 38 1 70 77
126. Maiya S., Hislop A. A., Flynn Y., Haworth S. G. Response to bosentan in children with pulmonary hypertension. Heart: 2006; 92 5 664 670
127. Rosenzweig E. B., Ivy D. D., Widlitz A., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol: 2005; 46 4 697 704
128. Taguchi M., Ichida F., Hirono K., et al. Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet: 2011; 26 3 280 287
129. van Loon R. L., Hoendermis E. S., Duffels M. G., et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist? Am Heart J: 2007; 154 4 776 782
130. Votava-Smith J. K., Perens G. S., Alejos J. C. Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt. Pediatr Cardiol: 2007; 28 4 314 316
131. Galiè N., Beghetti M., Gatzoulis M. A., et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation: 2006; 114 1 48 54
132. Beghetti M., Haworth S. G., Bonnet D., et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol: 2009; 68 6 948 955
133. Klinger J. R., Oudiz R. J., Spence R., Despain D., Dufton C. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol: 2011; 108 2 302 307
134. Oudiz R. J., Galiè N., Olschewski H., et al. ARIES Study Group. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol: 2009; 54 21 1971 1981
135. Galiè N., Olschewski H., Oudiz R. J., et al. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation: 2008; 117 23 3010 3019
136. Galié N., Badesch D., Oudiz R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol: 2005; 46 3 529 535
137. Takatsuki S., Rosenzweig E. B., Zuckerman W., Brady D., Calderbank M., Ivy D. D. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol: 2013; 48 1 27 34
138. Zuckerman W. A., Leaderer D., Rowan C. A., Mituniewicz J. D., Rosenzweig E. B. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol: 2011; 107 9 1381 1385
139. Humbert M., Barst R. J., Robbins I. M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J: 2004; 24 3 353 359
140. Simonneau G., Rubin L. J., Galiè N., et al. PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med: 2008; 149 8 521 530
141. Hoeper M. M., Markevych I., Spiekerkoetter E., Welte T., Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J: 2005; 26 5 858 863
142. Hanna B., Conrad C. Lung transplantation for pediatric pulmonary hypertension. Prog Pediatr Cardiol: 2009; 27 49 55
143. Lammers A. E., Burch M., Benden C., et al. Lung transplantation in children with idiopathic pulmonary arterial hypertension. Pediatr Pulmonol: 2010; 45 3 263 269
144. Schaellibaum G., Lammers A. E., Faro A., et al. Bilateral lung transplantation for pediatric idiopathic pulmonary arterial hypertension: a multi-center experience. Pediatr Pulmonol: 2011; 46 11 1121 1127
145. Goldstein B. S., Sweet S. C., Mao J., Huddleston C. B., Grady R. M. Lung transplantation in children with idiopathic pulmonary arterial hypertension: an 18-year experience. J Heart Lung Transplant: 2011; 30 10 1148 1152
146. Aurora P., Edwards L. B., Kucheryavaya A. Y., et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report-2010. J Heart Lung Transplant: 2010; 29 10 1129 1141